首页> 美国卫生研究院文献>Genome Research >A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells
【2h】

A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells

机译:全基因组的RNA干扰筛查可确定前列腺癌细胞中雄激素受体功能的新调节剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The androgen receptor (AR) is a mediator of both androgen-dependent and castration-resistant prostate cancers. Identification of cellular factors affecting AR transcriptional activity could in principle yield new targets that reduce AR activity and combat prostate cancer, yet a comprehensive analysis of the genes required for AR-dependent transcriptional activity has not been determined. Using an unbiased genetic approach that takes advantage of the evolutionary conservation of AR signaling, we have conducted a genome-wide RNAi screen in Drosophila cells for genes required for AR transcriptional activity and applied the results to human prostate cancer cells. We identified 45 AR-regulators, which include known pathway components and genes with functions not previously linked to AR regulation, such as HIPK2 (a protein kinase) and MED19 (a subunit of the Mediator complex). Depletion of HIPK2 and MED19 in human prostate cancer cells decreased AR target gene expression and, importantly, reduced the proliferation of androgen-dependent and castration-resistant prostate cancer cells. We also systematically analyzed additional Mediator subunits and uncovered a small subset of Mediator subunits that interpret AR signaling and affect AR-dependent transcription and prostate cancer cell proliferation. Importantly, targeting of HIPK2 by an FDA-approved kinase inhibitor phenocopied the effect of depletion by RNAi and reduced the growth of AR-positive, but not AR-negative, treatment-resistant prostate cancer cells. Thus, our screen has yielded new AR regulators including drugable targets that reduce the proliferation of castration-resistant prostate cancer cells.
机译:雄激素受体(AR)是雄激素依赖性和去势抵抗性前列腺癌的介体。原则上,识别影响AR转录活性的细胞因子可以产生降低AR活性并对抗前列腺癌的新靶标,但尚未确定对AR依赖性转录活性所需基因的全面分析。使用利用AR信号的进化保守性的无偏遗传方法,我们在果蝇细胞中进行了全基因组RNAi筛选,寻找AR转录活性所需的基因,并将结果应用于人前列腺癌细胞。我们确定了45种AR调节剂,其中包括已知的途径成分和具有以前与AR调节无关的功能的基因,例如HIPK2(一种蛋白激酶)和MED19(介体复合物的亚基)。人类前列腺癌细胞中HIPK2和MED19的减少降低了AR目标基因的表达,并且重要的是,减少了雄激素依赖性和去势抵抗性前列腺癌细胞的增殖。我们还系统地分析了其他介体亚基,并发现了一小部分介体亚基,这些亚基可以解释AR信号传导并影响AR依赖性转录和前列腺癌细胞的增殖。重要的是,通过FDA批准的激酶抑制剂对HIPK2的靶向研究显露了RNAi耗竭的作用,并减少了AR阳性而不是AR阴性的耐治疗性前列腺癌细胞的生长。因此,我们的筛选产生了新的AR调节剂,包括可降低去势抵抗性前列腺癌细胞增殖的可药物治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号